FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...

Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Avoidable mortality increased by an average of 33 deaths per 100,000 people across the United States from 2009 to 2019.

Crystal Dew World has released a major update to CrystalMark Retro 2.0.0, with its scope extended to cover Windows 95/98/Me ...

Apparently putting patients first warrants severe punishment. If Australia refuses to give Big Pharma unfettered access ...

As of December 31, 2024, Fortress' consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as ...

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).